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Table
Distribution of BCG scar positivity and presence of INH prophylaxis with
respect to TST values
Autologous HSCT Allogeneic HSCT
N¼320 N¼272
TST value Positive BCG scar/INH
prophylaxis/total # of
patients
Positive BCG scar/INH
prophylaxis/total # of
patients
0-4, 9 mm 68/13 /153 70/10/ 137
5- 9, 9 mm 21/14/ 37 24/16/ 33
10- 19, 9 mm 53/56/ 87 31/29/ 57
‡ 20 mm 5/9/ 17 7/7/ 8
data not available 26 37
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function to PB gamma delta T cells when culturing cells with
the NBP, Zometa (zoledronic acid), and IL-2. Fourteen days in
culture resulted in signiﬁcant fold increase in the prolifera-
tion of gamma delta Tcells and in the percent of lymphocytes
in both sample types. PB gamma delta T cells proliferated
more robustly than CB with a 288.60 versus 21.32 fold
increase, respectively. Additionally, in freshly isolated
samples, CB gamma delta T cells comprised an average of
1.404% of the lymphocyte population, which was similar to
PB gamma delta T cells, with an average of 2.319%. However,
by day 14, PB gamma delta T cells increased to 70.15% of
lymphocytes whereas CB gamma delta T cells increased to
12.49%. Phenotypically, we also examined TCRg9 and TCRd2
expression and found that the TCRg9d2 was a common clone
in freshly isolated PB gamma delta T cells, which predomi-
nated after 14 days in culture. However, while the TCRg9d2
variant was present in CB gamma delta T cells, it was low
before and after culture, suggesting that Zometa may not
stimulate gamma delta T cells in CB the same as PB. The
memory subsets of freshly isolated gamma delta T cells were
similar for CB and PB. Yet following culture, PB gamma delta
T cells were mostly CD45RO+ memory cells, speciﬁcally
effector or central memory subsets, with signiﬁcantly fewer
CD45RA+ naïve cells, whereas more CB gamma delta T cells
were of the intermediate CD45RA+CD45RO+ naïve subset. In
addition, we also observed thatmemory status corresponded
with the TCR variant; more Vg9 and Vd2 cells were memory
cells and Vd1 cells weremostly naïve. Functionally, PB and CB
gamma delta T cells had distinct cytokine secretion proﬁles
both before and after culture. PB gamma delta Tcells secreted
more IFNg and TNFa after culture, while CB gamma delta T
cells secreted more IL-10 and RANTES. As limited TCRgd
phenotypic reagents are available, we developed a single cell
PCR assay for genotypic analysis of the TCRgd repertoire. PCR
analysis suggests that the TCRgd repertoire of freshly isolated
cells is diverse in both samples types, with more variation
among the CB gamma delta T cells, while TCRg9d2 is most
prevalent in PB. Further analysis of the variant subsets is
warranted and may give insight into how each of these
receptor pairings affects gamma delta T cell function.SUPPORTIVE CARE330
The Role of Tuberculin Skin Test As a Guide to Preventive
Chemotherapy for Latent Tuberculosis Infection in
Hematopoietic Stem Cell Transplantation in a Region
with Intermediate Prevalence and Routine BCG
Vaccination: A Preliminary Report from Turkey
Sahika Zeynep Aki 1, Gulsan Turkoz Sucak 1,
Ozlem Guzel Tunccan 2, Nurdan Kokturk 3, Esin Senol 2.
1 Hematology, Gazi University Faculty of Medicine, Ankara,
Turkey; 2 Infectious Disease, Gazi University Faculty of
Medicine, Ankara, Turkey; 3 Pulmonary Medicine, Gazi
University Faculty of Medicine, Ankara, Turkey
Turkey is a country with intermediate tuberculosis (TB)
prevalence (24 cases per 100,000 population) where BCG
vaccination is mandatory. Immunocompromised patients are
at risk for TB infection. However, tuberculin skin test (TST)
has limitations in immunocompromised patients while
diagnosing latent TB infection (LTBI) and commencing
isoniazid (INH) chemoprophylaxis. After 2000 consensus
statements recommended INH prophylaxis in higher risk
patients with a cut-off TST value of 5 mm. This retrospectivestudy was conducted to determine the frequency of TB in
HSCT recipients and the role of chemoprophylaxis with
different cut-off values of TST (<5 mm, 5 to 10 mm, 10 to 20
mm, and 20 mm) in a region with intermediate TB
prevalence.
Patients and Methods: Five hundred and ninety two
patients [320 (54 %) autologous and 272 (46 %) allogeneic]
transplanted at our center between September 2003 and July
2014 and survived for 100 days post-transplantation were
included. The median age was 51 years-old (range 16-71) in
autologous and 29 years-old (range 15-64) in allogeneic
HSCT recipients. The decision to initiate INH prophylaxis was
usually based on universal guidelines howevermodiﬁcations
were also made at the discretion of the pulmonologist
responsible for the pre-transplantation consultation or the
new released guidelines. Anergy was deﬁned as any reaction
size of 0 to 2 mm in diameter.
Results: BCG scar datawas available in 148 of 320 autologous
(46.3 %) and 133 of 272 (48.9 %) allogeneic HSCT recipients.
Distribution of positive BCG scar and INH prophylaxis with
respect to TST values are given in table. Anergy was detected
in 141 (44.1 %) of autologous and 124 (45.7 %) of allogeneic
HSCT recipients. Positive BCG vaccination scar data was
available in 47% of anergic patients. Ninety-two (28.8%) of
autologous and 64 (23.5 %) of allogeneic HSCT recipients
received INH prophylaxis. None of the allogeneic HSCT
recipients and 1 in 320 (0.3 %) patients in autologous HSCT
developed TB. This patient was TST anergic prior to
transplantation and was not on chemoprophylaxis.
Conclusion: Our data showed low frequency of TB after
HSCT despite variable chemoprophylaxis practices. Recent
guidelines recommended reduction of TST threshold to 5
mm in higher risk patients. However our results suggest that
these general guidelines do not apply to all patients and all
regions.331
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Background: Early detection and treatment of fungal
sinusitis is critical in the successful treatment of these
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been shown to be unhelpful in the diagnosis of fungal
disease. We therefore initiated the practice of nasal
endoscopy as part of our evaluation of HSCT patients who
had prolonged fever.
Methods: We performed a retrospective review of all
children who underwent HSCT at our institution from
January 2011 until June 2014. Children were identiﬁed who
underwent nasal endoscopy after a minimum of three days
of fever despite the initiation of broad-spectrum antibiotics
and who had negative bacterial blood cultures. The results of
the endoscopy and any cultures obtained were reviewed.
Demographic, clinical, microbiologic, management and
outcome data were collected.
Results: A total of 44 nasal endoscopieswereperformed in 42
children. Threeof the childrenhadpositivenasal endoscopies.
Two were asymptomatic and were found to have suspicious
lesions which were subsequently biopsied. Thesewere found
to be positive for Fusarium spp andRhizopus spp. The thirdhad
rapid development of eye swelling and sinus pain and was
found to have Rhizopus spp. The three children were then
treated with aggressive serial debridement and initiation of
multiagent antifungal therapy. All three of the children sur-
vived their fungal infection although one remains on anti-
fungal therapy.Mild discomfort during the procedurewas the
onlyadverse event related to the use of endoscopy reported in
this patient group. In those with a negative endoscopy, there
were no children who subsequently developed fungal sinus
disease. Three of these patients were later identiﬁed with a
fungal infection at other sites: one had bipolaris spp of the
skin, one had Aspergillus ﬂavus isolated from an endotracheal
tube aspirate and one had disseminated Histoplasmosis
capsulatum isolated on post-mortem examination.
Conclusions: We conclude that nasal endoscopy is safe and
effective in the evaluation of pediatric HSCT patients as part
of the evaluation of prolonged fever to rule out fungal
sinusitis. Early detection of fungal sinusitis by nasal
endoscopy and aggressive surgical and antifungal therapy
may improve the survival of HSCT patients.332
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Introduction: Letermovir (MK-8228) is a potent, once-daily
inhibitor of the cytomegalovirus (CMV) terminase complex
that is being developed for the prophylaxis of CMV
infection in transplant patients. This study evaluated the
pharmacokinetic interactions, safety and tolerability of
letermovir when coadministered in healthy subjects with
mycophenolate mofetil (MMF), which is the morpholi-
noethyl ester prodrug of mycophenolic acid (MPA).
Materials & Methods: This was an open label trial in 14
healthy female subjects that explored the pharmacokidsnetic
parameters of a single 1 mg oral dose of MMF administered
alone on day 1 and administered on day 12 with letermovir
given orally as 480 mg once daily from day 8 and continued
through day 16. Letermovir pharmacokinetics were assessedat single dose (day 5) and at steady state on day 12 (with
MMF) and on day 16 (alone following MMF washout).
Results: Coadministration of a single dose of 1 mg of MMF
with 480 mg daily letermovir at steady state had no effect on
the pharmacokinetics of MPA. The MPA AUC0-inf and Cmax
geometric mean ratios (GMRs) [90% conﬁdence interval] for
the comparison (MMF with letermovir/MMF alone) were
1.08 [0.96, 1.21] and 0.96 [0.81, 1.13], respectively. Coadmin-
istration of 480 mg daily letermovir at steady state with a
single dose of 1 mg MMF has no clinically meaningful effect
on the pharmacokinetics of letermovir with AUC0-24 and
Cmax GMR of 1.18 [1.04, 1.33] and 1.11 [0.92, 1.35], respec-
tively. The letermovir geometric mean accumulation ratio
(Day 16/Day 5) and 95% CI were 1.13 [0.90, 1.42] for AUC0-24
and 1.01 [0.79, 1.28] for Cmax, indicating that accumulation of
letermovir when administered as daily doses is minimal. All
related AEs were reported as mild in severity and resolved.
Following coadministration of letermovir and MMF, no
clinically meaningful changes were observed in clinical
laboratory values, vital signs, ECG or physical exam results.
Conclusions: Multiple dose administration of 480 mg leter-
movirdailywith a single doseof 1mgMMFwasgenerallywell
tolerated by the healthy subjects in this study. Co-adminis-
tration of letermovir with MMF had no clinically meaningful
effect on the PK of letermovir or MMF. Letermovir and MMF
may be coadministered without dose adjustment.333
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Introduction: While AH & ITP are recognized after CBT, the
incidence, severity, treatment response, & prognosis of these
complications is not established.
Methods: We evaluated AH/ITP in a day 100 landmark
analysis of 152 double-unit CBT recipients (median age 38
years, range 0.9-70) who were transplanted for hematologic
malignancies, engrafted & disease-free.
Results: Nine patients [median age 42 years (range 2-54),
median follow-up 50.6 months (range 7.6-105.4) have
developed autoimmune cytopenias (7 AH, 1 ITP, 1 both) for a
6% (95%CI: 3-11) 3-year cumulative incidence [median onset
8.6 months (range 5.8-24.5), Figure]. Six patients had severe
disease (Hb < 6 gm/dl &/or platelets < 20). Their lowest
counts (Hb 2.6-6.8 & platelets 0-4) were a median of 1 day
(range 0-94) after diagnosis. Six had grade II-IV acute
GVHD prior to AH/ITP, and all 9 patients developed AH/ITP
in the context of immunosuppression taper. There was no
association between AH/ITP and age, diagnosis, regimen
intensity, or recipient CMV serostatus. Treatment in the
ﬁrst week was IVIg/corticosteroids/rituximab in 3 patients,
whereas CSA dose was increased in 1, 2 had IVIg only, 2
